Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.62 |
| ▸ | AHR | P35869 | 5/20 | 0.49 |
| ▸ | CMA1 | P23946 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | TDP2 | O95551 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PNLIP | P16233 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484612 | 0.90 | MAOB (0.50) | EIF2AK2AHRCMA1EGFRERBB2 | |
| SCHEMBL3483943 | 0.81 | EIF2AK2 (0.57) | EIF2AK2AHRCMA1EGFRERBB2 | |
| SCHEMBL397588 | 0.79 | EIF2AK2 (0.74) | EIF2AK2AHRCMA1CA9MAOB | |
| SCHEMBL30468520 | 0.77 | CA9 (0.70) | EIF2AK2AHRCMA1CA9TDP2 | |
| SCHEMBL398137 | 0.77 | CA9 (0.70) | EIF2AK2AHRCMA1CA9TDP2 | |
| Hydrochloric Acid SCHEMBL9833199 | 0.75 | CA9 (0.68) | EIF2AK2AHRCMA1CA9TDP2 | |
| SCHEMBL3484815 | 0.74 | EGFR (0.49) | AHRCMA1EGFRERBB2CA9 | |
| SCHEMBL3484193 | 0.74 | EGFR (0.49) | EGFRERBB2CA9PDE7AHTR2A | |
| SCHEMBL3484676 | 0.74 | AHR (0.56) | AHREGFRERBB2TDP2 | |
| Methylamine SCHEMBL28015139 | 0.74 | CA9 (0.66) | EIF2AK2AHRCMA1CA9TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101611041-A | Condensed heterocyclic compouds | TAKEDA PHARMACEUTICAL (JP) | 2009-12-23 | — | — | CN | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | EIF2AK2 1327/4885AHR 259/4885CMA1 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.